Research chair established in honor of Dr. Novick
The Cleveland Clinic Glickman Urological Institute has established a $2 million education and research chair in honor of its chairman, Andrew C. Novick, MD.
The Cleveland Clinic Glickman Urological Institute has established a $2 million education and research chair in honor of its chairman, Andrew C. Novick, MD.
The Andrew C. Novick Distinguished Chair in Urology is dedicated to furthering patient care, research, education, and outstanding physician leadership within the Glickman Urological Institute. Dr. Novick will be the first physician to hold the chair.
The chair will be held now and in perpetuity by the chairman of the Glickman Urological Institute. The chairman will determine the research and education needs in the field of urology.
“I am deeply thankful for the generosity of our patients and friends,” Dr. Novick said. “A distinguished chair is a visionary investment in the work done at Cleveland Clinic in which our patients are the direct beneficiaries.”
AUA, SUFU publish 2024 guideline for idiopathic overactive bladder
April 25th 2024“This brand new guideline offers options for all patients with OAB with a focus on shared decision-making between patients with OAB and clinicians, as well as a personalized, tailored approach to care,” said Cameron and Smith.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
